scholarly journals The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men

2018 ◽  
Vol 13 (1) ◽  
pp. 155798831881828 ◽  
Author(s):  
Luyao Zhang ◽  
Ke Cai ◽  
Yu Wang ◽  
Wen Ji ◽  
Zhen Cheng ◽  
...  
Keyword(s):  
Hypogonadotropic Hypogonadism ◽  
Serum Testosterone ◽  
High Serum ◽  
Serum Testosterone Level ◽  
Common Side Effect ◽  
Human Menopausal Gonadotropin ◽  
Luteinizing Hormone Level ◽  
Contributing Factors ◽  
Congenital Hypogonadotropic Hypogonadism ◽  
Serum Luteinizing Hormone

The objective of this study was to compare the effect of pulsatile gonadorelin pump (PGP) and cyclical gonadotropin (human chorionic gonadotropin [HCG]/human menopausal gonadotropin [HMG]) therapy (CGT) on spermatogenesis in congenital hypogonadotropic hypogonadism (CHH) men. Twenty-eight azoospermic CHH males were included in this nonrandomized study. Ten received PGP and 18 received CGT. The primary endpoint was the earliest time spermatogenesis occurred during 24 months of treatment. Spermatogenesis time was significant earlier in the PGP group than the CGT group (median of 6 and 14 months, respectively, χ2 = 6.711, p = .01). Spermatogenesis occurred in 90% of the PGP group and 83.3% of the CGT group and showed statistically insignificant difference in the superiority analysis and the no-inferior test. Contributing factors significant for spermatogenesis were previous HCG/or testosterone treatment and the peak serum luteinizing hormone level of triptorelin stimulation test at baseline. Although testis volume and penile length increased significantly from baseline, the differences between the two therapies were not significant. There was a tendency for high serum testosterone level, associated with more facial acne and breast tenderness in the CGT group. Skin allergic erythema scleroma was a common side effect of the PGP. In summary, PGP resulted in earlier spermatogenesis and more desirable testosterone levels than CGT.

scholarly journals NIFEDIPINEON;

2019 ◽  
Vol 26 (02) ◽  
Author(s):  
Sidra Hamid ◽  
Qaiser Aziz ◽  
Aneela Jamil ◽  
Lubna Meraj ◽  
Shazia Muazam ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Luteinizing Hormone ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Control Group ◽  
Channel Blockers ◽  
Sprague Dawley ◽  
Study Objective ◽  
Serum Luteinizing Hormone ◽  
Sprague Dawley Rats

Background: The most potent and effective drugs used for the management of blood pressure in hypertensive patients are Calcium channel blockers (CCBs). Nifedipine, a CCB, acts by blocking entry of calcium ions all the way through the voltage gated calcium channels (VGCCs) of L-type present in the smooth muscle cells of blood vesselsand reducing the blood pressure by decreasing the peripheral vascular resistance. Objectives: The study objective was to determine the effect of nifedipine on serum luteinizing hormone (LH) and serum testosterone in male Sprague Dawley rats. Study Design: Animal experimental study. Setting: All experiments were conducted at the Research laboratory of Shifa College of Medicine, Islamabad along with National Institute of Health (NIH), Islamabad. Period: October, 2012 to April, 2014. Methods: The study was done on adult male Sprague-Dawley rats (N= 60) aged 90-120 days old and their body weights varied between 200 + 50 grams. Rats were divided intotwo groups (n=30). Group A was administered0.5 ml distilled water/rat daily orally, group B was administered orally with nifedipine 50 mg/kg/rat dissolved in 1ml of DMSO. All the doses were given to rats for 8 weeks. After 8 weeks, serum luteinizing hormone and serum testosterone were measured in both groups. Results: In Nifedipine treated group, serum testosterone was significantly decreasedand serum LH was unaffected as compared to the control group. Conclusion: Nifedipine has adverse effects on male fertility as it decreases serum testosterone level.

scholarly journals The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty

2003 ◽  
pp. 23-29 ◽  
Author(s):  
V Degros ◽  
C Cortet-Rudelli ◽  
B Soudan ◽  
D Dewailly
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Testosterone Level ◽  
Pubertal Development ◽  
Hypogonadotropic Hypogonadism ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Delayed Puberty ◽  
Hcg Test

OBJECTIVE: The effectiveness of biological investigations aiming at discriminating isolated hypogonadotropic hypogonadism (IHH) from constitutional delayed puberty (CDP) in male patients is still controversial. We revisited the diagnostic power of the basal serum testosterone level, the Triptorelin test and the human chorionic gonadotropin (hCG) test in a cohort of 33 boys with delayed puberty. DESIGN: Boys were aged 14.2 to 26.2 Years at referral. A 5-Year-long clinical follow-up after the initial study allowed confirmation of the diagnosis. At the end of the follow-up period, IHH was found in 13 patients while the other 20 had normal spontaneous pubertal development (CDP). RESULTS: At referral, a basal morning testosterone level >1.7 nmol/l was observed in 55% of patients with CDP exclusively (predictive positive value (PPV)=100%; predictive negative value (PNV)=59%). For CDP, the PPV of the LH peak 3 h after Triptorelin was 100% by setting the upper threshold at 14 IU/l and the PNV was 72%. However, no lower threshold could discriminate IHH from CDP in the remaining patients with an LH peak 3 h after Triptorelin <14 IU/l. In CDP patients, the PPV of the serum testosterone increment after hCG stimulation (deltaT/hCG) was 100% for values >9 nmol/l (PNV=72%). In IHH patients, the PPV of deltaT/hCG was 100% for values <3 nmol/l (PNV=82%). Only 29% of the studied population had a deltaT/hCG between these lower and upper thresholds and therefore could not have been classified initially. CONCLUSIONS: (i) Dynamic testing for the diagnosis of delayed puberty is useful only when the basal testosterone level is lower than 1.7 nmol/l; (ii) in that case, the hCG test has better discriminating power than the Triptorelin test and appears as the best cost-effective investigation. It prevents useless and expensive investigations in about one-half of CDP patients with a basal morning testosterone level lower than 1.7 nmol/l.

Anastrazole treatment in breast cancer does not cause androgenic effect

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10614-10614
Author(s):  
M. Mundia ◽  
M. F. Ali
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Common Side Effect ◽  
Breast Cancers ◽  
Testosterone Levels ◽  
Hormone Receptor Positive ◽  
Oncology Practice ◽  
Androgenic Effect

10614 Background: Aromatse Inhibitors are a class of drugs that inhibit tumor growth in hormone receptor positive breast cancers in postmenopausal women. They exert their action by inhibiting the enzyme aromatse involved in the last step in conversion of Androgens to estrogens. They are currently used extensively in both advanced and adjuvant treatments. Methods: Clinical Charts of postmenopausal women, with estrogen receptor positive breast cancer, receiving the non-steroidal aromatse inhibitor, Anastrazole 1 mg daily at a community oncology practice were evaluated for androgenic effect of the drug. Review included presence of clinical Hirsutism and serum testosterone levels. Results: There were 33 women, receiving Anastrazole, 29 for adjuvant therapy, and 4 for metastatic disease. Age 51–77years (median: 63 years), Duration of Anastrazole therapy 6 months to 42 months (median: 18 months), There was no Clinical evidence of hirsutism noted. Serum testosterone levels varied from 9 ng/ml to 58 ng/ml. (Normal range: 14–76 ng/ml) in 32 women. 1 woman had a serum testosterone level of 86 ng/ml with no clinical hirsutism. The most common side effect of Anastrazole was arthralgias, seen in three women. Conclusions: Anastrozole 1 mg daily does not appear to cause any clinical androgenic effect, or elevation of serum testosterone levels. No significant financial relationships to disclose.

Identification of a novel mutation of NR0B1 in a patient with X-linked adrenal hypoplasia and symptomatic treatment

2017 ◽  
Vol 30 (12) ◽  
Author(s):  
Jing Yang ◽  
Yuncheng Lv ◽  
Ye Zhou ◽  
Xinhua Xiao
Keyword(s):  
Frameshift Mutation ◽  
Novel Mutation ◽  
Hypogonadotropic Hypogonadism ◽  
Serum Testosterone ◽  
Symptomatic Treatment ◽  
Serum Testosterone Level ◽  
Coding Region ◽  
Rapid Improvement ◽  
Congenital Adrenal Hypoplasia ◽  
Adrenal Hypoplasia

AbstractBackground:X-linked congenital adrenal hypoplasia (X-linked AHC) is characterized by acute onset of primary adrenal insufficiency in infancy or early childhood and hypogonadotropic hypogonadism (HH) at puberty. Mutations inMethods:The entire coding region of theResults:DNA sequencing revealed a missense mutation (c.383-384 insA) in exon 1, which resulted in a novel frameshift mutation, thereby resulting in a truncated protein (p.Leu129 Pro fs*137). The therapeutic trail with an observation period of 20 weeks showed an effective improvement in symptoms of hypogonadism with human chorionic gonadotropin (HCG) administration, including a rapid improvement of serum testosterone level, descending of testicles as well as enlargement of testicles and growth of penis.Conclusions:Our study identified a novel frameshift mutation of the

Failure to induce puberty in a man with X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism by pulsatile administration of low-dose gonadotropin-releasing hormone

1987 ◽  
Vol 114 (1) ◽  
pp. 153-160 ◽  
Author(s):  
Kiyoshi Kikuchi ◽  
Masayuki Kaji ◽  
Toru Momoi ◽  
Haruki Mikawa ◽  
Yosuke Shigematsu ◽  
...  
Keyword(s):  
Hypogonadotropic Hypogonadism ◽  
Serum Testosterone ◽  
Repeated Administration ◽  
Serum Testosterone Level ◽  
Endogenous Opioid ◽  
Pituitary Dysfunction ◽  
Congenital Adrenal Hypoplasia ◽  
Serum Lh ◽  
Pulsatile Administration ◽  
Adrenal Hypoplasia

Abstract. To elucidate the mechanism of hypogonadotropic hypogonadism in a patient with X-linked congenital adrenal hypoplasia, we studied the effects on serum LH and FSH of repeated iv administration of GnRH (400 μg, over 2 h, once a day, for 14 consecutive days), pulsatile sc administration of GnRH (5 μg every 90 min during days 1 ~ 56, 10 μg every 90 min during days 57 ~ 91) and an iv bolus injection of 10 mg of naloxone. The repeated administration of GnRH restored the hyporesponsiveness of serum FSH and increased serum testosterone level from < 1.0 to 1.7 nmol/l, but the impaired LH response to the standard GnRH test was not improved. The pulsatile administration of GnRH for 91 consecutive days did not induce a clinical or a biochemical change of puberty. Serum testosterone remained undetectable < 1.0 nmol/l, the hyporesponsiveness of serum LH was not improved, but basal FSH level was significantly increased and the impaired FSH response to the standard GnRH test was slightly improved. Naloxone had no effect on serum LH or FSH before or during the pulsatile administration. We conclude that hypogonadotropic hypogonadism in our patient is due to the pituitary dysfunction and that the endogenous opioid peptides may not play a role in the mechanism of inhibited gonadotropin secretions.

Gonadotropins for testicular descent in cryptorchid congenital hypogonadotropic hypogonadism males beyond infancy

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Shreya Sharma ◽  
Ravikumar Shah ◽  
Virendra Patil ◽  
Anurag R. Lila ◽  
Vijaya Sarathi ◽  
...  
Keyword(s):  
Semen Analysis ◽  
Hypogonadotropic Hypogonadism ◽  
Sperm Concentration ◽  
Inhibin B ◽  
Testicular Descent ◽  
Total Testosterone ◽  
Human Menopausal Gonadotropin ◽  
Beneficial Effects ◽  
Congenital Hypogonadotropic Hypogonadism

Abstract Objectives To study the effect of combined gonadotropin therapy (CGT) on testicular descent ± spermatogenesis in congenital hypogonadotropic hypogonadism (CHH) patients with cryptorchidism beyond infancy. Methods This retrospective cohort study included CHH patients with cryptorchidism [bilateral (n=5) or unilateral (n=1)] treated with CGT for testicular descent ± pubertal induction. All participants were treated with CGT [human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG)] with hMG pretreatment in three and monitored for changes in testicular volume (TV), serum total testosterone (T), serum inhibin-B, and sperm concentration. Results Complete testicular descent to the scrotal position was achieved in 5/6 patients (10/11 testes) after 4.7 ± 1.6 months of treatment. There was 44 ± 18%, 97.5% (IQR: 44–195), 10-fold (IQR: 3–19.6), and two-fold (IQR: 1.7–9.3) increase in stretched penile length, ultrasound measured TV, T level, and serum inhibin-B from baseline, respectively. In two pediatric cases, testicular descent occurred with isolated hMG therapy. At the last follow up (median: 23.5, IQR: 10.5–38.7 months), all the descended testes remained in scrotal position. In four pubertal/postpubertal age patients, continuous CGT (18–60 months) yielded T and inhibin-B levels of 16.64 ± 1.46 nmol/l and 106 ± 32.6 pg/mL, respectively. All the three patients with available semen analysis had sperm concentration of ≥5 million/mL and one of them achieved paternity. Conclusions A trial of CGT before orchiopexy may be considered in CHH males with cryptorchidism even beyond the narrow age-window of infancy. CGT may also have beneficial effects on future spermatogenesis and fertility outcomes in these patients.

Sign in / Sign up

Export Citation Format

Share Document